CAPTRUST Financial Advisors’s Palvella Therapeutics PVLA Stock Holding History

CAPTRUST Financial Advisors’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$723K	Buy	4,731 +1,174	+33%	+$142K	﹤0.01%	1931
2026 Q1	$443K	Buy	+3,557	New	+$371K	﹤0.01%	2115
2022 Q3	–	Sell	-13	Closed	-$2K	–	4167
2022 Q2	$2K	Hold	13	–	–	﹤0.01%	4531
2022 Q1	$3K	Hold	13	–	–	﹤0.01%	4402
2021 Q4	$4K	Hold	13	–	–	﹤0.01%	4207
2021 Q3	$5K	Hold	13	–	–	﹤0.01%	3969
2021 Q2	$4K	Hold	13	–	–	﹤0.01%	3971
2021 Q1	$3K	Hold	13	–	–	﹤0.01%	3951
2020 Q4	$2K	Hold	13	–	–	﹤0.01%	3172
2020 Q3	$2K	Hold	13	–	–	﹤0.01%	2822
2020 Q2	$3K	Buy	+13	New	+$3.04K	﹤0.01%	2533
2019 Q4	–	Sell	-6	Closed	-$2K	–	1856
2019 Q3	$2K	Hold	6	–	–	﹤0.01%	1819
2019 Q2	$2K	Buy	+6	New	+$1.79K	﹤0.01%	1829
2018 Q2	–	Hold	0	–	–	–	1620
2018 Q1	–	Hold	0	–	–	–	1391

Other funds holding PVLA

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

CAPTRUST Financial Advisors's PVLA Position: Q2 2026 in Review

CAPTRUST Financial Advisors increased its Palvella Therapeutics (PVLA) stake by 33% in Q2 2026, buying an estimated $142K and bringing the position to 4,731 shares worth $723K. The position accounts for ﹤0.01% of the portfolio, ranked #1931.

CAPTRUST Financial Advisors first reported a position in PVLA in Q2 2019 and has held it in 13 quarters since. 197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

CAPTRUST Financial Advisors held 4,731 shares of Palvella Therapeutics worth $723K as of Q2 2026.
CAPTRUST Financial Advisors bought 1,174 Palvella Therapeutics shares in Q2 2026, an estimated $142K.
Palvella Therapeutics made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #1931 holding.
CAPTRUST Financial Advisors first reported a position in Palvella Therapeutics in Q2 2019 and has held it in 13 quarters since.
197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.